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(cIMT) and the presence of carotid plaques or stenosis were 
recorded.  Results: Higher cIMT was found to be indepen-
dently associated with lower MDRS scores when this score 
was less than the quartile limit (p = 0.02). Only a trend for a 
positive association was detected between cIMT and the 
Rankin score (p = 0.06). There was no significant association 
between carotid markers and the occurrence of stroke or 
MRI parameters except for diffusion data. The mean and 
peak values of MRI diffusion histograms were found posi-
tively associated with the presence of plaques (p  ! 0.01). 
 Conclusion: The results suggest that the severity of athero-
sclerosis may relate to cognitive decline in CADASIL and that 
this effect is possibly related to the degree of microstruc-
tural cerebral tissue lesions. Longitudinal studies are needed 
to confirm these results.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 CADASIL (cerebral autosomal dominant arteriopathy 
with subcortical infarcts and leukoencephalopathy) is a 
small vessel disease of the brain caused by mutations in 
the  NOTCH3 gene  [1] . The clinical hallmarks of CADA-
SIL include attacks of migraine with aura, recurrent lacu-
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 Abstract 
 Purpose: Cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASIL) is a 
cerebral small vessel disease caused by mutations of the 
 NOTCH3 gene. Marked variations in disease severity have 
raised the hypothesis that non-genetic factors may modu-
late the expressivity of the phenotype. The aim of the current 
study was to evaluate whether atherosclerosis, assessed by 
carotid duplex ultrasonography, is associated with variations 
in the clinical and MRI phenotype of CADASIL.  Methods: 
Data from 144 consecutive patients enrolled in an ongoing 
prospective cohort study were collected. Degree of disabil-
ity was assessed by the modified Rankin Scale, that of cogni-
tive impairment by the Mattis Dementia Rating Scale (MDRS). 
The total volume of the brain, of lacunar lesions and of white 
matter hyperintensities, the number of cerebral microhem-
orrhages, and parameters derived from histograms of appar-
ent diffusion coefficient were measured on cerebral MRI. 
Atherosclerosis was evaluated by B-mode ultrasonography 
of carotid arteries. Both the carotid intima-media thickness 
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nar stroke, mood disturbances and progressive subcorti-
cal dementia  [2–4] .
 To date, with the exception of rare mutations in the 
EGFR10-11 domain that may affect the clinical expression 
of the disease, no obvious genotype/phenotype has been 
demonstrated  [5–7] . However, some data suggest that 
classical vascular risk factors may influence the outcome 
in CADASIL. In a previous series, Singhal et al.  [5] found 
that active smoking was associated with younger age at 
first ischemic manifestation. In a cross-sectional study, 
Viswanathan et al.  [8] recently observed that higher levels 
of HbA 1C and systolic blood pressure were related to the 
number of cerebral microhemorrhages on gradient-echo 
imaging. Recently, Adib-Samii et al.  [9] reported that hy-
pertension and smoking were associated with an in-
creased risk of stroke in 200 CADASIL patients.
 In the general population, the carotid intima-media 
thickness (cIMT) and the presence of carotid plaques 
evaluated by duplex ultrasonography are considered as 
early markers of atherosclerosis and have been associated 
with the severity of systemic atherosclerosis  [10, 11] . They 
are also independent predictors of both cardiovascular 
and cerebrovascular events  [12, 13] . Moreover, cIMT has 
been associated with white-matter hyperintensities on 
T 2 -weighted MRI and with cognitive decline in elderly 
people as were arterial stiffening and endothelial dys-
function  [14] . Whether the severity of atherosclerosis can 
modulate the expression of a specific small vessel disease 
not related to the current vascular risk factors remains 
unknown.
 In the present study, we hypothesized that atheroscle-
rosis assessed by carotid duplex ultrasonography might 
have an impact on the clinical or brain MRI phenotype 
of CADASIL.
 Subjects and Methods 
 Subjects 
 Subjects were drawn from an ongoing prospective cohort study 
of consecutive patients with CADASIL in Lariboisière Hospital, 
Paris, between June 2003 and November 2006. Complete study 
design has been detailed elsewhere  [8, 15] . In summary, in 144 ge-
netically confirmed CADASIL patients, clinical and demographic 
data were collected. They underwent a general and neurological 
examination, including an evaluation of the degree of disability 
based on the modified Rankin Scale (mRS) (poor outcome was 
defined as mRS  6 3). Neuropsychological evaluation with the 
Mattis Dementia Rating Scale (MDRS)  [16] was also performed. 
The educational level was assessed with a scale from 1 (illiterate) 
to 7 (university diploma). Note that history of hypertension was 
defined as previous diagnosis of hypertension ( 1 140/90) or use of 
antihypertensive treatment for control of blood pressure.
 All patients had cerebral MRI and cervical ultrasound exami-
nation. All patients had blood drawn for laboratory screening in-
cluding: complete blood count, glucose, hemoglobin A 1c (HbA 1c ), 
cholesterol panel, triglycerides, homocysteine, fibrinogen and 
CRP.
 Informed consent was obtained from each subject or from a 
relative if the patient was not able to give written consent. The 
study was approved by an independent ethic committee.
 Magnetic Resonance Imaging 
 Cerebral MRI scans were obtained by the use of a 1.5-T system 
(Signa General Electric Medical Systems). 3D T 1 -weighted se-
quences, fluid-attenuated inversion recovery (FLAIR), T 2 * -
weighted gradient-echo planar and diffusion-weighted imaging 
were performed. The methods used for MRI analysis and the val-
idation of the different measurements have been detailed else-
where  [8, 15] .
 White matter hyperintensities (WMH) lesions were analyzed 
on FLAIR images. The total volume of WMH was normalized to 
the intracranial cavity (ICC) in each patient [normalized volume of 
WMH or nWMH = (volume of WMH/volume ICC)   100]. To as-
sess the total volume of lacunes, all hypointense lesions with both 
a signal identical to that of cerebrospinal fluid and a diameter 
 1 2 mm were selected. The total volume of lacunes in each patient 
was normalized to the ICC [normalized lacunar volume or nLV = 
(volume of lacunes/volume ICC)   100]. Microhemorrhages were 
defined as rounded foci  ^  5 mm in diameter hypointense on 
 gradient-echo sequences and distinct from vascular flow voids, 
 leptomeningeal hemosiderosis, or non-hemorrhagic subcortical 
mineralization. The number of microhemorrhages was recorded in 
each patient. Histograms of apparent diffusion coefficient (ADC) 
values  from  ADC  maps  were  generated  for  each  patient using a 
bin width equal to 0.1  ! 10 –4 mm 2 s –1 . Voxels containing cerebro-
spinal fluid were excluded in all patients before calculation using a 
superior threshold value at 27  ! 10 –4 mm² s –1 . To correct for cross-
subject differences in brain volume, each histogram was normal-
ized to the total number of brain tissue voxels. Both the mean ADC 
and diffusion value at the peak (peak value) derived from each his-
togram were used for analysis. Due to small changes in diffusion 
values after the upgrade of the MR device and coils that occurred 
during the study, the analysis of diffusion data was restricted to the 
104 patients who had their examination before the upgrade. Deter-
mination of global brain volumes from 3D T 1 sequences was per-
formed using the BrainVISA software (CEA, Orsay, France; http://
brainvisa.info) as previously detailed  [17] . Brain parenchymal frac-
tion (BPF) was defined as the ratio of brain tissue volume to total 
intracranial cavity volume (BPF = brain tissue volume/ICC).
 Ultrasonography 
 Participants had a cervical ultrasound B-mode examination 
(Acuson, 7-MHz probe) performed at inclusion. All examinations 
were performed by trained physicians. Longitudinal and cross-
sectional ultrasound images were taken bilaterally throughout 
the extracranial portion of the common carotid artery (CCA) and 
of the bifurcation and origin of the internal carotid artery bilater-
ally. Plaque was defined as a focal structure encroaching into the 
lumen of at least 0.5 mm or a thickening  6 1.5 mm (distance be-
tween media-adventitia interface to the intima-lumen interface) 
and stenosis was defined as a plaque of more than 20% of the lu-
men axe in cross section  [18] . Carotid atherosclerosis lesions were 
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classified as either no plaque or presence of plaque or stenosis. As 
recommended, the near and far walls of the middle parts of the 
right and left CCA were scanned longitudinally to assess the best 
angle of incidence for cIMT measurements. Then an average 
cIMT measurement was performed on a 10-mm segment at the 
far wall of each CCA using dedicated software (M’Ath  -Std © ). 
The average of right and left CCA IMT measurements was used 
for analysis. The inter- and intrarater reliability was not calcu-
lated in the present study but was previously assessed in large 
studies and was found to be good  [19] .
 Statistical Methods 
 Analyses were conducted using SAS  software v.9.1 (SAS In-
stitute Inc., Cary, N.C., USA). Data are summarized as frequen-
cies and percentages for categorical data and as mean and stan-
dard deviation for continuous variables. Odds ratios (OR) are re-
ported with 95% confidence intervals (95% CIs).
 First analysis was performed to identify factors associated 
with carotid plaques or stenosis and with cIMT among the follow-
ing variables: age, sex, educational level, history of hypertension, 
history of hypercholesterolemia, history of diabetes, smoking sta-
tus, systolic blood pressure, diastolic blood pressure, body mass 
index, HDL, LDL, total cholesterol, triglycerides, HbA 1C , blood 
glucose, homocysteine, CRP, and fibrinogen level.
 The second analysis used the same procedure to identify cor-
relations between clinical and radiological markers of CADASIL 
by adding either carotid plaque or stenosis and cIMT among the 
evaluated factors.
 For binary endpoints (presence of carotid plaques or stenosis, 
presence of stroke, disability, cognitive impairment and micro-
hemorrhages), univariate logistic regressions were first per-
formed. Variables statistically significant at a 15% threshold in the 
univariate analysis were then introduced into a multivariable 
stepwise logistic regression to identify independent correlates of 
these endpoints. Validity of all models was evaluated by the boot-
strapping procedure (n = 1,000 bootstrap samples).
 For the continuous measures (cIMT, extent of white matter le-
sions, total volume of lacunes, BPF and mean ADC), Pearson cor-
relation coefficients were obtained, and multivariable stepwise lin-
ear regressions were used to find the linear models that best predict 
continuous measures. Resampling procedures were used for vali-
dation of these models. The significance level was fixed at 5%.
 Results 
 Main Cohort Characteristics 
 The mean age in the cohort was 52.6  8 11.9 years (me-
dian 52.8, range 24.1–77.5) and 72 men (50%) were includ-
ed. Ninety-three subjects (64.6%) had at least one ischemic 
stroke before inclusion and 32 (22.2%) had a mRS  6 3. The 
median MDRS score was 140 and its lower quartile limit 
was 127. The frequency of vascular risk factors was as fol-
lows: history of hypertension (n = 24/144 subjects, 16.7%), 
Table 1. L ogistic regression according to the presence of carotid plaques or stenosis and linear regression with cIMT
Variable Plaques (n = 48/144 patients) cIMT (n = 134 patients)
univariate analysis multivariate analysis u nivariate analysis multivariate analysis
OR [95% CI] p value OR [95% CI] p value Pear son
correlation
coefficient
p value p value
Age (10-year increase) 2.34 [1.60; 3.44] <0.0001 2.49 [1.64; 3.79] <0.0001 0.644 <0.0001 <0.0001
Sex (male vs. female) 2.80 [1.36; 5.78] 0.0053 3.11 [1.39; 6.97] 0.0059 0.149 0.0852
Educational level 1.17 [0.94; 1.47] 0.1559 –0.294 0.0007 0.0034
History of high blood pressure
(yes vs. no) 1.52 [0.62; 3.74] 0.3590 0.039 0.6529
History of hypercholesterolemia
(yes vs. no) 1.70 [0.84; 3.42] 0.1385 0.086 0.3225
History of diabetes (yes vs. no) 0.99 [0.09; 11.19] 0.9931 –0.107 0.2201
Current or ex-smoker (yes vs. no) 1.26 [0.63; 2.53] 0.5149 0.021 0.8091
SBP, mm Hg 1.02 [1.00; 1.04] 0.0297 0.102 0.2527
DBP, mm Hg 1.01 [0.98; 1.04] 0.5364 0.039 0.6613
BMI 0.98 [0.90; 1.07] 0.6598 0.052 0.5901
HDL, mmol/l 0.72 [0.30; 1.74] 0.4662 –0.026 0.7777
LDL, mmol/l 1.22 [0.85; 1.76] 0.2775 0.106 0.2223
Total cholesterol, mmol/l 1.18 [0.89; 1.57] 0.2434 0.103 0.2367
Triglycerides, mmol/l 2.00 [1.10; 3.63] 0.0223 0.140 0.1070
Glycated hemoglobin 1.29 [0.63; 2.65] 0.4882 0.084 0.3355
Blood glucose, mmol/l 0.98 [0.70; 1.38] 0.9047 –0.027 0.7577
Homocysteine, mol/l 1.03 [0.95; 1.11] 0.5136 0.168 0.0551
CRP, mg/l 1.00 [0.95; 1.05] 0.9374 0.099 0.2542
Fibrinogen, g/l 1.48 [0.91; 2.40] 0.1125 0.315 0.0003
 Carotid Atherosclerotic Markers in 
CADASIL 
Cerebrovasc Dis 2011;31:246–252 249
hypercholesterolemia (n = 65, 45.5%), diabetes (n = 3, 
2.1%), current or ex-smoking (n = 69, 48.3%).
 Vascular Risk Factors and Carotid Atherosclerosis 
 ( table 1 ) 
 Carotid plaques or stenosis were found in 48 out of 144 
patients (33.3%). In univariate analysis, carotid plaques or 
stenosis were found associated with age, male sex and sys-
tolic blood pressure ( table 1 ), in multivariate analysis the 
association was found significant only with age and male 
sex.
 134 out of 144 patients had cIMT measurement avail-
able. The mean cIMT was 0.63  8 0.1 mm (median 0.61, 
range 0.47–0.91). cIMT was found associated with age, 
educational level, and fibrinogen in univariate analysis, 
only with age and educational level in multivariate analy-
sis (see  table 1 ).
 Main Clinical Manifestations and Carotid 
Atherosclerosis  ( table 2 ) 
 Cognition 
 Using the median MDRS score of 140 as the cutoff 
value for the presence of moderate cognitive impairment, 
we found, in univariate analysis, that age, educational 
level, cIMT, the presence of plaques, a positive history of 
hypercholesterolemia and homocysteine level were sig-
nificantly associated with MDRS  ! 140. In multivariate 
analysis, only higher age and lower educational level were 
independently correlated with moderate cognitive im-
pairment (AUC 0.777 [0.968; 0.857], optimism 0.77%).
 When using the lower quartile limit of MDRS (127) as 
the cutoff value for the presence of severe cognitive im-
pairment, while univariate analysis showed a significant 
association with cIMT, the presence of plaques, age, male 
sex, educational level, hypercholesterolemia and fibrino-
gen level, multivariate analysis showed that only higher 
cIMT and older age were the only factors independently 
associated with lower cognitive performances (AUC 
0.833 [0.761; 0.905], optimism 0.75%).
 Disability and  Stroke 
 Thirty-two out of 144 (22.2%) patients were disabled 
(mRS  6 3). In  table 3 , the factors associated with mRS  6 3 
and stroke in multivariate analysis are presented. When 
the inclusion of the variable ‘age’ was forced in the model, 
we found higher age and lower level of HbA 1C indepen-
dently associated with disability and a trend for an asso-
ciation between higher cIMT and disability.
Table 2.  Logistic regression using MDRS score at 140 or at 127 as cutoff values for the presence of cognitive impairment
Variable MDRS ≤140 (n = 68/130 patients) MDRS ≤127 (n = 35/130 patients)
univariate analysis multivariate analysis univariate analysis m ultivariate analysis
OR [95% CI] p value OR [95% CI] p value OR [95% CI] p value OR [95 % CI] p value
cIMT (0.05-mm increase) 1.50 [1.20; 1.88] 0.0004 1.77 [1.39; 2.26] <0.0001 1.40 [1.05; 1.88] 0.0234
Plaques (yes vs. no) 1.16 [0.55; 2.42] 0.6988 2.64 [1.18; 5.91] 0.0179
Age (10-year increase) 2.17 [1.52; 3.10] <0.0001 2.10 [1.46; 3.06] 0.0001 3.20 [1.97; 5.21] <0.0001 2.19 [1.24; 3.87] 0.0069
Sex (male vs. female) 1.98 [0.98; 3.98] 0.0556 1.96 [0.89; 4.35] 0.0969
Educational level 0.63 [0.49; 0.81] 0.0003 0.64 [0.49; 0.84] 0.0011 0.75 [0.56; 1] 0.0472
History of high blood pressure
(yes vs. no) 2.69 [0.97; 7.46] 0.0568 0.85 [0.29; 2.53] 0.7723
History of hypercholesterolemia
(yes vs. no) 2.56 [1.25; 5.23] 0.01 2.42 [1.08; 5.42] 0.0310
History of diabetes (yes vs. no) 1.88 [0.17; 21.23] 0.611 1.41 [0.12; 16.06] 0.7823
Current or ex-smoker (yes vs. no) 0.91 [0.46; 1.82] 0.7889 0.71 [0.32; 1.56] 0.3951
SBP, mm Hg 1.01 [0.99; 1.03] 0.4442 1.01 [0.99; 1.04] 0.3783
DBP, mm Hg 1 [0.97; 1.03] 0.8926 1 [0.96; 1.04] 0.9789
BMI 1.06 [0.97; 1.17] 0.1974 1 [0.9; 1.12] 0.9474
HDL, mmol/l 0.61 [0.26; 1.46] 0.2686 0.4 [0.14; 1.13] 0.0841
LDL, mmol/l 0.92 [0.64; 1.3] 0.6225 0.75 [0.51; 1.12] 0.1581
Total cholesterol, mmol/l 0.95 [0.72; 1.24] 0.7057 0.79 [0.58; 1.07] 0.1261
Triglycerides, mmol/l 1.54 [0.85; 2.79] 0.1538 1.35 [0.75; 2.43] 0.3144
Glycated hemoglobin 1.32 [0.62; 2.8] 0.4765 0.69 [0.28; 1.69] 0.4156
Blood glucose, mmol/l 0.95 [0.68; 1.33] 0.7687 0.72 [0.5; 1.03] 0.0740
Homocysteine, mol/l 1.09 [1; 1.2] 0.0444 1.08 [0.99; 1.18] 0.0958
CRP, mg/l 1.01 [0.97; 1.06] 0.6327 1.04 [0.99; 1.09] 0.1335
Fibrinogen, g/l 1.4 [0.85; 2.29] 0.1876 1.97 [1.12; 3.48] 0.0186
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 Ninety-three out of 144 patients had a history of symp-
tomatic stroke. The multivariate analysis revealed only 
higher age and male sex to be independently associated 
with stroke in the cohort but not the markers of athero-
sclerosis (cIMT and plaques).
 Brain MRI Markers and Atherosclerosis 
 The significant associations observed in multivariate 
analysis are presented in  table 3 ; the extent of white mat-
ter lesions in the 144 CADASIL patients was only associ-
ated with age but not with the other parameters ( table 3 ).
 For the total volume of lacunes, we found a significant 
association with increasing age and with lower HDL lev-
el. The mean ADC was independently associated with the 
presence of plaques or stenosis, higher age and higher 
LDL. The same significant association was obtained be-
tween peak value of diffusion histograms and both high-
er LDL and the presence of plaques. The presence of two 
or more microhemorrhages was associated with increas-
ing age and with higher systolic blood pressure. BPF was 
inversely correlated with age and was significantly lower 
in men compared to women.
 Discussion 
 In this large prospective cohort of CADASIL patients, 
we found that atherosclerosis has an impact, although 
small, on the clinical phenotype of this genetic non-ath-
erosclerotic vascular disease of the brain. Indeed, in pa-
tients with the lowest cognitive performances, cIMT and 
age were found to be independently and inversely corre-
lated with the MDRS. Interestingly, this association was 
not detected in patients with moderate cognitive impair-
ment in whom age and education level were the only pre-
dictors of cognitive performances. These results first 
confirm the major role of aging in the course of CADA-
SIL and second suggest that educational level may have a 
positive impact on cognitive function in CADASIL dur-
ing its early stages, while atherosclerosis may play a nega-
tive role at more advanced stage of the disease when cog-
nitive decline has already occurred. However, the identi-
fied link between atherosclerosis and cognitive decline in 
this cohort of CADASIL patients does not mean neces-
sarily a causal relationship. First, cognitive impairment 
may magnify vascular risk factors through a reduction of 
self-care. Second, atherosclerosis and dementia may share 
Table 3. S ummary of factors associated with different clinical or MRI markers after multivariate analysis
Clinical and MRI variable
tested in the model
Markers with
significant association
Regression
parameter1 [95% CI]
p AUC [95% CI]
or R2, optimism
mRS ≥3 (n = 32/144) cIMT (0.05-mm increase) 1.31 [0.99; 1.72] 0.0598 0.809 [0.725; 0.894]
age (10-year increase) 2.10 [1.22; 3.61] 0.0073 2%
glycated hemoglobin 0.12 [0.03; 0.49] 0.003
Clinical history of stroke age (10-year increase) 1.56 [1.14; 2.14] 0.0055 0.662 [0.562; 0.763]
(n = 93/144) sex (male vs. female) 2.38 [1.15; 4.93] 0.0191 1.3%
WMH age 0.19 [0.13; 0.25] <0.0001 21.2%
1.7%
Total volume of lacunes age 0.04 [0.02; 0.05] 0.0002 11.9%
LDL –0.06 [–0.11; –0.00] 0.0389 2.6%
Mean ADC presence of carotid plaques 1.09 [0.42; 1.76] 0.0018 27.4%
or stenosis 5.5%
age 0.04 [0.01; 0.07] 0.0121
LDL –0.57 [–0.94; –0.20] 0.0029
BPF age –0.25 [–0.36; –0.14] <0.0001 29.2%
sex –3.70 [–6.18; –1.22] 0.0039 3.4%
Presence of microhemorrhages age (10-year increase) 1.84 [1.08; 3.15] 0.0248 0.758 [0.654; 0.862]
systolic blood pressure 1.03 [1.00; 1.06] 0.0292 1.5%
1 Regression parameter stands for OR and 95% CI or slope and 95% CI in logistic regression or linear regression, respectively. Only 
significant results obtained in multivariate analysis are shown.
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common unknown risk factors including potential ge-
netic factors. Interestingly, cIMT has also been associated 
with more severe cognitive alterations in cohort studies 
of Alzheimer’s disease  [20–22] . Our data suggest that ath-
erosclerosis may also have an impact on the course of 
non-atherosclerotic small vessel disease of the brain.
 In the present study, we were unable to demonstrate 
any strong association between atherosclerosis and dis-
ability assessed by mRS, which is a score more correlated 
to motor than cognitive impairment. We also failed to 
show any significant association between atherosclerosis 
and the occurrence of stroke in CADASIL. It is, however, 
known that the frequency of stroke is not a major deter-
minant of clinical severity in CADASIL, which at its ad-
vanced stages has a more progressive course  [15] .
 Since cognitive impairment is strongly related to brain 
MRI lesions in CADASIL, we searched for an association 
between the most important MRI markers of the disease 
and carotid markers of atherosclerosis. The presence of 
carotid plaques or stenosis was found to be significantly 
associated with both the mean and peak values of cere-
bral diffusion histograms. These findings suggest that 
atherosclerosis may interact with the severity of micro-
structural cerebral tissue lesions in CADASIL. In con-
trast, in multivariate analysis, no significant association 
was detected between cIMT or carotid plaques or stenosis 
and the total load of lacunar infarctions, extent of WMH, 
number of microhemorrhages, or BPF. As expected, age 
was found to be strongly associated with all studied brain 
MRI parameters of the disease  [2] .
 This study has several limitations. First, we did not use 
quantitative data such as the surface or volume of carotid 
plaques, which may be more specific for the evaluation of 
the severity of atherosclerosis than the degree of carotid 
stenosis  [23] . Second,  we did not consider in the multi-
variate analysis the impact of the underlying Notch3 mu-
tations nor studied other genotypes like ApoE. However, 
although ApoE genotype is strongly related to cognitive 
impairment in the general population, it has not been 
found to be associated with the clinical severity of CA-
DASIL  [5] . In addition, there is no data to support a gen-
otype phenotype correlation in CADASIL  [9] , except rare 
mutations within the ligand-binding domain of Notch3 
that may influence the phenotype of the disease  [7] . Fur-
thermore, when the analyses were performed after exclu-
sion of the 8 patients harboring this mutation in EGFR10-
11 in the cohort, the overall results remained unchanged 
(data not shown). Finally, there are also different biases 
related to this cohort of a rare disorder that may also pre-
clude to observe stronger effects of atherosclerosis and a 
significant association between cIMT and the usual vas-
cular risk factors such as the relatively young age of par-
ticipants, their selection based on the presence of MRI 
lesions not explained by vascular risk factors, their high 
education level, active prevention of vascular risk factors 
and strong medical follow-up.
 In conclusion, the results of this study suggest that ath-
erosclerosis may influence, although subtly, the cognitive 
decline in CADASIL, which may occur through an in-
crease in microstructural cerebral tissue loss. Longitudi-
nal studies in larger population of patients are needed to 
confirm the impact of atherosclerosis on the phenotype 
of the disease and to determine whether treating classical 
vascular risk factors of atherosclerosis may improve the 
course of the disease.
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